Shots:

• UCB to receive $150M up front and is eligible to receive milestones upon regulatory approvals and achievement of development and sales-related milestones with a total consideration of $1.5B. The alliance will co-develop & co-fund the development of UCB0599 globally
• The agreement will combine UCB's expertise with Novartis' global capabilities & deep experience in transformative disease-modifying treatments to expand the development of UCB0599 for PD
• UCB will be the marketing authorization holder & commercial lead in the EU & Japan while Novartis in the US & other countries & gets the right for the co-development of UCB7853 upon completion of the P-I program

 Ref: PR Newswire | Image: Novartis